We analyzed mRNA expression data from the NeoPalAna trial (GSE93204)30 to assess the associations among MAP3K3 expression, the YAP signature, and drug resistance in patients with luminal breast cancer (Fig. 4p). Here, MAP3K3 is linked to breast carcinoma.